Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.